通过SGLT2抑制剂减少血清尿酸:来自系统性审查和元分析的证据
Shiwen Yang1,2, Qiaozhi Hu1, Kexin Liu1
1Department of Pharmacy, West China Hospital, Sichuan University, Chengdu, China.
Frontiers in pharmacology
|July 4, 2025
概括
与安慰剂相比,-葡萄糖-同载体-2 (SGLT2) 抑制剂显著降低血清尿酸 (SUA). 恩帕格利弗洛辛 (empagliflozin) 显示了最大的SUA减少,而索塔格利弗洛辛的影响最小.
科学领域:
- 内分泌学 在内分泌学.
- 腎臟病學 (nephrology) 是一種醫學專業.
- 心脏病学 心脏病学
背景情况:
- 血清尿酸 (SUA) 的升高与不良健康结果有关.
- -葡萄糖-同载体-2 (SGLT2) 抑制剂可以降低血糖和血清尿酸.
- 关于SGLT2抑制剂的SUA降低作用的比较数据有限.
研究的目的:
- 系统地评估各种SGLT2抑制剂对SUA水平的影响.
- 为了比较不同SGLT2抑制剂在减少SUA方面的疗效.
- 为SUA管理提供基于证据的药物选择信息.
主要方法:
- 51个随机对照试验 (RCT) 的系统审查和元分析.
- 搜索了主要的数据库 (PubMed,Embase,Cochrane,ClinicalTrials.gov) 截至2024年3月.
- 评估了SUA水平和痛风发病率的变化,使用Cochrane偏差风险和GRADE方法.
主要成果:
- 与安慰剂相比,所有SGLT2抑制剂都显著降低了SUA (MD = -32.14 μmol/L).
- 恩帕格利弗洛辛证明了最显著的SUA减少 (MD = -45.61 μmol/L).
- 索塔格利弗洛辛显示SUA减少最少 (MD = -13.72 μmol/L),而痛风发病率没有显著差异.
结论:
- SGLT2 抑制剂在降低 SUA 水平方面是有效的.
- 这些发现支持SGLT2抑制剂作为高风险人群的潜在多因素疗法.
- 由于SUA减少的证据质量不佳,可能需要进一步的研究.
相关概念视频
Dipeptidyl Peptidase 4 Inhibitors
269
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
269
Phase II Reactions: Glucuronidation
813
Glucuronidation, a pivotal phase II biotransformation process, involves the coupling of glucuronic acid to a drug or xenobiotic. Given its widespread occurrence and critical role in drug metabolism, it's considered the most crucial phase II reaction. It enhances the water solubility of substances, aiding their expulsion from the body. The driving force behind these reactions is a group of enzymes known as UDP-glucuronosyltransferases (UGTs). UGTs facilitate the transfer of a glucuronic acid...
813
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
271
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
271
Urinary Tract Calculi III: Medical Management
28
The diagnosis of renal calculi involves several imaging techniques, including non-contrast CT scans and ultrasound. These methods help visualize kidney stones, assess their size and location, and detect possible obstructions. Additionally, Measuring urine pH is useful for diagnosing specific stone types, such as struvite (alkaline pH) and uric acid stones (acidic pH). Cystine stones are primarily linked to cystinuria, a genetic condition. A urinalysis helps detect blood in the urine (hematuria)...
28
Oral Hypoglycemic Agents: Sulfonylureas
349
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
349
Oral Hypoglycemic Agents: Biguanides and Glitazones
309
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
309
![Quantitative SERS Detection of Uric Acid via Formation of Precise Plasmonic Nanojunctions within Aggregates of Gold Nanoparticles and Cucurbit[n]uril](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F61682.jpg&w=3840&q=50)

